How Lactulose Works to Lower Ammonia Levels

Lactulose lowers ammonia levels through several reinforcing mechanisms in the gut, not a single clean pathway. It is a synthetic sugar that passes through the stomach and small intestine completely undigested, arriving intact in the colon where bacteria ferment it into organic acids. This fermentation drops the local pH, shifts the composition of gut bacteria, and accelerates the movement of intestinal contents toward the exit. The combined effect is that less ammonia enters the bloodstream from the colon, which is why lactulose has been the primary treatment for hepatic encephalopathy for decades, even though researchers still debate which of its mechanisms matters most.

Why Lactulose Survives to the Colon

Lactulose is a disaccharide made of galactose and fructose, but the bond linking them is not one that human digestive enzymes can break. There is no enzyme on the surface of small intestinal cells capable of splitting lactulose apart.¹ This is what separates it from ordinary lactose, which gets cleaved in the small intestine by lactase. Because lactulose arrives in the colon whole, it becomes food exclusively for colonic bacteria. That selectivity is the foundation of everything else lactulose does.

The Acid Trap

When colonic bacteria ferment lactulose, they produce short-chain fatty acids, primarily acetate, propionate, and butyrate. These acids accumulate rapidly. In one study measuring portal blood directly during surgery, short-chain fatty acid concentrations rose within 15 to 45 minutes of lactulose being placed in the cecum.² The surge of organic acids drives the local pH down, sometimes to pH 5 or below.

This acidification creates what is sometimes called an “acid trap” for ammonia. Ammonia (NH₃) is a small, uncharged molecule that moves freely across cell membranes and the gut wall. But in an acidic environment, ammonia picks up a hydrogen ion and becomes ammonium (NH₄⁺), which is charged and cannot easily cross back into the blood. The theory is that the low colonic pH pulls ammonia out of the bloodstream into the gut lumen, where it gets trapped as ammonium and expelled in stool.³

The acid-trap idea is elegant, and it was the original explanation for how lactulose works. But subsequent research has complicated the picture. In one fecal incubation experiment, acidifying the environment with hydrochloric acid did reduce how much new ammonia was generated, but unlike lactulose, plain acidification did not actually lower the existing ammonia concentration. Lactulose did both: it reduced ammonia production and pulled down ammonia that was already present, suggesting that fermentation itself was doing something beyond just lowering pH.⁴ That “something” turns out to involve the bacteria themselves.

Shifting the Bacterial Population

Lactulose does not just feed existing bacteria faster; it changes which bacteria thrive. In patients with liver cirrhosis given lactulose, the proportion of Bifidobacterium increased while Bacteroides decreased.⁵ This matters because different bacterial species handle nitrogen differently. Some bacteria produce urease, an enzyme that breaks down urea into ammonia, effectively generating more of the toxin the liver-compromised body cannot clear. Lactulose appears to suppress these urease-producing populations.

Broader analyses of colonic microflora during lactulose use confirm this pattern. Probiotic species increase while putrefactive bacteria and potential pathogens decline. Along with those shifts come measurable reductions in urease activity and in aromatic compounds associated with bacterial protein breakdown.⁶ So lactulose achieves a double effect on bacteria: it promotes organisms that consume ammonia for their own growth and simultaneously suppresses organisms that produce ammonia as a metabolic byproduct.

Interestingly, the Japanese cirrhosis study found that fecal organic acid levels did not actually change much with lactulose treatment, even as bacterial populations shifted dramatically. The authors concluded that lactulose was suppressing urease-forming bacteria independent of acidification.⁵ This finding sits awkwardly alongside the acid-trap theory, which is part of why researchers today describe lactulose’s mechanism as multi-pronged rather than attributable to any single pathway.

Bacteria as Ammonia Sponges

Growing bacteria need nitrogen to build proteins and nucleic acids. When lactulose gives colonic bacteria an abundant energy source, their population expands, and that expanding population soaks up ammonia as a nitrogen source for growth. This bacterial assimilation effect was demonstrated in fecal incubation studies: fermentable substrates like lactulose caused bacteria to incorporate ammonia into their own biomass, physically removing it from the surrounding environment.⁴ The ammonia-laden bacteria are then eliminated in stool.

Animal data supports this interpretation. In dogs fed lactulose, apparent nitrogen absorption dropped while fecal nitrogen excretion rose, consistent with the idea that more nitrogen was being locked into bacterial mass and expelled rather than absorbed into the bloodstream. The result was less ammonia reaching the liver and less nitrogen showing up in urine.⁷ For a cirrhotic liver already struggling to convert ammonia to urea, that reduction in incoming ammonia is the whole therapeutic point.

The Osmotic Laxative Effect

Lactulose also works as a simple osmotic laxative. Because it is not absorbed, it draws water into the colon and speeds up transit time. Faster transit means less time for bacteria to generate ammonia from dietary protein remnants, and less time for any ammonia present in the colon to be absorbed into the blood. This cathartic effect is the most immediately noticeable consequence of taking lactulose and is both its primary therapeutic action for constipation and its most common source of side effects when used for hepatic encephalopathy.

The laxative action is probably why polyethylene glycol (PEG), a purely osmotic agent with no fermentation properties, has shown some promise in treating hepatic encephalopathy as well. A meta-analysis found PEG led to faster resolution of encephalopathy symptoms during the first 24 hours compared to lactulose alone and shortened hospital stays.⁸ A randomized trial combining PEG with lactulose found that the combination improved encephalopathy scores at 24 hours more than lactulose alone, though blood ammonia levels at that point were similar between the two groups.⁹ The disconnect between clinical improvement and ammonia levels is a recurring theme in this field and underscores how much we still do not understand about what drives encephalopathy symptoms.

The Gut Barrier Connection

Liver cirrhosis does not just impair ammonia clearance. It also damages the gut barrier itself. In advanced cirrhosis, the intestinal lining becomes more permeable, a state sometimes described as “leaky gut,” allowing bacteria, bacterial toxins, and inflammatory molecules to cross into the bloodstream. Endotoxin levels in the blood rise and contribute to the worsening cycle of portal hypertension, kidney dysfunction, and systemic inflammation.¹⁰

Lactulose’s bacterial-reshaping effect may help here beyond ammonia control. By promoting beneficial organisms and suppressing pathogenic ones, lactulose could reduce the bacterial translocation and endotoxin load that compound the liver’s problems. This is harder to measure clinically than ammonia levels, but it adds another layer to why lactulose remains a first-line therapy despite the existence of alternatives that address ammonia through different routes.

Clinical Evidence for Treating Hepatic Encephalopathy

Lactulose has been used for hepatic encephalopathy since the 1960s, and the clinical evidence supporting it has accumulated over decades. In a double-blind trial comparing lactulose with the sugar alcohol lactitol, roughly 69% of lactulose-treated patients were clinically normal by the end of treatment.¹¹ For prevention of recurrence, a randomized controlled trial found lactulose effective at reducing episodes of encephalopathy compared to placebo.¹²

Where lactulose has shown especially compelling results is in minimal hepatic encephalopathy, a subtler condition where patients do not have obvious confusion but perform poorly on cognitive tests and report reduced quality of life. In one trial, three months of lactulose treatment dramatically reduced the number of abnormal neuropsychological test results and improved quality-of-life scores, with benefits directly tied to cognitive improvement.¹³ A larger multicenter trial found that about 64% of patients with minimal hepatic encephalopathy reversed the condition after 60 days of lactulose, compared to roughly 23% who improved without treatment.¹⁴

Acute episodes are trickier. In the HELP trial comparing lactulose to PEG for overt encephalopathy, only about half of lactulose-treated patients showed any improvement on a standardized grading scale within 24 hours, and just 8% reached a fully normal score in that time frame.¹⁵ Lactulose works, but it is not fast-acting, and severe episodes often need additional interventions.

Adding Rifaximin to Lactulose

Rifaximin is a non-absorbed antibiotic that stays in the gut and reduces ammonia-producing bacteria through a different pathway. The combination of rifaximin and lactulose has become standard practice in many settings, and the evidence behind it is solid. A meta-analysis of seven randomized trials enrolling over 800 patients found that adding rifaximin to lactulose increased the proportion of patients who improved and reduced mortality compared to lactulose alone.¹⁶

A separate pooled analysis quantified the benefit: the combination needed to treat about four to five patients to see one additional clinical improvement beyond what lactulose alone would achieve, and about five to nine patients treated to prevent one additional death. Hospital stays were also shorter with the combination, and the rate of side effects was not higher than with lactulose alone.¹⁷ Rifaximin’s main practical barrier is cost; lactulose is inexpensive and generic, while rifaximin is considerably more expensive in most markets.

Lactulose Versus Lactitol

Lactitol is another non-absorbed sugar alcohol that works by a similar fermentation principle. Head-to-head, the two perform about the same. A meta-analysis found no statistical difference in clinical improvement, mortality, blood ammonia levels, or the composite encephalopathy index between the two.¹⁸ The one consistent difference is side effects: lactulose causes more flatulence and gastrointestinal discomfort than lactitol.¹⁹ Despite this, lactulose remains far more widely prescribed, largely because of its longer track record and broader availability.

The Adherence Problem

Lactulose’s effectiveness in clinical trials does not always translate to real-world results, and the main reason is that patients struggle to keep taking it. The drug tastes unpleasantly sweet, doses are large in volume, it needs to be taken multiple times a day, and the side effects are the kind people find hard to live with: unpredictable diarrhea, bloating, cramping, and gas. In a study examining barriers to adherence, patients who did not stick with their lactulose cited every one of these factors significantly more than adherent patients. Among non-adherent patients, nearly half reported the dosing frequency as difficult or very difficult, and over 60% found the taste unpleasant.²⁰

The consequences of poor adherence are stark. In a long-term prophylaxis study, three-quarters of patients on lactulose experienced a recurrence of overt encephalopathy. Among those who recurred, over a third were non-adherent, and the most common reason was gastrointestinal side effects.²¹ This is a frustrating catch-22: the drug works, but the side effects that prove it is working (loose stools, gas) are exactly what drives people to stop taking it. The standard clinical goal is to titrate the dose until the patient has two to three soft bowel movements per day, but hitting that target without tipping into frank diarrhea is harder than it sounds.

Rectal Administration

When a patient with severe encephalopathy cannot swallow or is too confused to take oral medication safely, lactulose can be given as a retention enema. The procedure involves diluting a large volume of lactulose solution with saline and administering it rectally, often repeated every 12 hours.²² This route delivers the drug directly to the colon, bypassing the swallowing issue entirely.

Evidence suggests rectal lactulose can be effective even for severe presentations. In one study of patients with grade 3 or 4 encephalopathy (the most severe levels, with marked confusion to coma), 80% showed complete reversal within 24 hours of lactulose enema treatment, rising to 90% at 48 hours.²³ Rectal administration is not commonly used for long-term management, but in the acute hospital setting it fills an important gap when the oral route is off the table.

Lactulose for Non-Liver Causes of High Ammonia

High ammonia does not always come from liver disease. Certain medications, particularly the seizure drug valproic acid, can raise ammonia levels as a side effect. You might expect lactulose to help in these situations too, since it works in the gut and the gut is where much of the body’s ammonia originates regardless of the underlying cause. In practice, the evidence is thin. A study of critically ill patients with valproic acid-induced high ammonia found no significant difference in ammonia reduction over 48 hours among patients treated with lactulose, levocarnitine (a supplement that supports ammonia metabolism through a different pathway), or the two combined.²⁴ The mechanism of ammonia elevation in these cases is different from cirrhosis, arising from effects on mitochondrial metabolism rather than gut-generated ammonia overwhelming a failing liver, so it makes sense that a gut-focused intervention would be less effective. If your doctor prescribes lactulose for high ammonia unrelated to liver disease, the rationale is weaker, and it is reasonable to ask about alternative approaches.